General

1 min read

On October 15, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Foundayo (orforglipron) for the treatment of type 2 diabetes and weight management.

Key Points

  • Regulatory Status: This is a positive recommendation, not final European Commission marketing authorization or product launch.
  • Clinical Use: Like other GLP-1 receptor agonists, orforglipron aims to improve glycemic control and aid weight management.
  • Dosing: Foundayo is being developed as an oral tablet.

Consult the existing Foundayo guide on theglpspot.com for earlier clinical trial context.

The weekly GLP-1 email

Plain-English answers on side effects, eating, cost and the newest medications. Free, one email a week.

The weekly GLP-1 email

Plain-English answers on side effects, eating, cost and the newest medications. Free, one email a week.

We respect your privacy. Unsubscribe anytime.

Next up

A few related reads to keep your momentum.

General
General
Written by
J
Jeremy H.
GLP-1 Nutrition Researcher

Nutrition researcher and founder of The GLPSpot. Jeremy built this site after watching friends and family struggle with the nutritional challenges of reduced appetite on GLP-1 medications — loss of muscle mass, dehydration, and nutrient deficiencies.

Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.